View ValuationIntervacc 将来の成長Future 基準チェック /26Intervacc利益と収益がそれぞれ年間3.8%と87.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-37.8% 19.4%なると予測されています。主要情報3.8%収益成長率19.44%EPS成長率Biotechs 収益成長22.9%収益成長率87.2%将来の株主資本利益率-37.83%アナリストカバレッジLow最終更新日22 May 2026今後の成長に関する最新情報Breakeven Date Change • Mar 30Forecast breakeven date pushed back to 2025The analyst covering Intervacc previously expected the company to break even in 2024. New forecast suggests losses will reduce by 40% per year to 2024. The company is expected to make a profit of kr24.0m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2024The 3 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of kr59.6m in 2024. Average annual earnings growth of 94% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 22Forecast breakeven date pushed back to 2023The analyst covering Intervacc previously expected the company to break even in 2022. New forecast suggests losses will reduce by 22% to 2022. The company is expected to make a profit of kr4.00m in 2023. Average annual earnings growth of 104% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.70m in 2022. Average annual earnings growth of 129% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 04Forecast to breakeven in 2023The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr69.3m in 2023. Average annual earnings growth of 128% is required to achieve expected profit on schedule.Breakeven Date Change • May 27Forecast breakeven pushed back to 2023The 2 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2022. The company is expected to make a profit of kr69.3m in 2023. Average annual earnings growth of 118% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Camilla McCarthy is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 15Intervacc AB (Publ) Appoints Emil Billbäck as ChairpersonIntervacc AB (publ) held its Annual General Meeting on 13 May 2026, and Emil Billbäck was elected as the Board of Directors' new chairperson for the period up to and including the next AGM.お知らせ • May 13Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026Intervacc AB (publ) announced the recruitment of Lars Stubberud as Chief Technology Officer (CTO), effective July 15, 2026. Lars Stubberud, M.Sc. Pharm, Ph.D., has more than 30 years' experience from the pharmaceutical industry, with responsibilities and expertise spanning broad CMC, product development, formulation, technology transfer, supply chain management, quality control and CMC regulatory affairs. He most recently held the position of Vice President Quality Assurance, Quality Control/Analytical Development at Calliditas Therapeutics AB, Stockholm, Sweden. The management team also comprises Jan Persson, CFO, Anna-Carin Lagerlöf, Head of Sales and Marketing, and Andrew Waller, Chief Scientific Officer.お知らせ • Apr 18Intervacc AB Announces Approval and Launch of Strangvac Vaccine in IcelandIntervacc AB (publ) announced that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses worldwide. However, it has not been permitted to import horses into Iceland for over 1,000 years and so this country retains the only strangles-free horse population in the world. Whilst horses within Iceland do not develop strangles, they have no natural immunity and are highly susceptible to this disease should they come into contact with S. equi. This has been a longstanding issue for horses exported from Iceland to other parts of the world. Strangvac is the only vaccine against strangles that generates a protective immune response, whilst still permitting the diagnosis of horses that have been exposed to, or are infected with, S. equi. This unique feature enables continued disease surveillance to provide evidence in support of Iceland's disease-free status and the protection of exported horses, which is important for Iceland's veterinarians and horse breeders, as well as the new owners. This approval is particularly noteworthy as the vaccination of horses to protect against infectious diseases is generally prohibited in Iceland, making the decision both unique and highly significant.お知らせ • Mar 20Intervacc AB Publ Announces Breakthrough Protection Against Streptococcus Suis Infection in PigletsIntervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating sows and transferring maternal immunity to piglets. The protection was proven in two separate challenge studies. Streptococcus suis is an important worldwide endemic swine pathogen, which causes meningitis, septicemia, arthritis, and endocarditis in weaned piglets between 4 and 10 weeks of age. Mortality rates can be as high as 20% in some farms and the total cost of S. suis infection in pigs is estimated to more than EUR 250 million annually in Europe alone. As of today, there are no approved vaccines available against S. suis infection in pigs. The experimental infection model involved the intravenous administration of a high dose of the virulent serotype 9 strain of S. suis (ST16) to induce systemic disease. The study showed that vaccination of pregnant sows was safe and provided statistically significant protection (total clinical score; p = 0.017) to piglets compared with piglets from an unvaccinated control group. The vaccine has previously conferred statistically significant protection to piglets against a virulent serotype 2 strain (ST1). The vaccine is administered to pregnant sows by intramuscular injection making it simple and cost-effective for pig farmers to use. The subunit vaccine, which is based on Intervacc's platform using recombinant fusion proteins, is designed to give protection against a wide range of S. suis strain types, using conserved, immunogenic, and virulence-associated proteins from S. suis. S. suis serotype 2 strains are the most common global cause of severe disease in piglets. Serotype 9 is currently less prevalent than serotype 2 but is increasingly responsible for severe pig diseases in Europe. Protection from a vaccine against multiple S. suis serotypes has been sought after by the pig farming industry for many years. Intervacc is the first company to show that a vaccine protected piglets against the highly virulent serotypes 2 (ST1) and 9 (ST16). This is a major breakthrough since the strains used in the studies are not closely related and the vaccine was only administered to pregnant sows with subsequent transfer of maternal immunity to their piglets. It is estimated that S. suis accounts for one-third of the total antibiotic usage in weaner pigs. A safe and efficacious vaccine against S. suis would reduce the need for antibiotics and the global threat from antimicrobial resistance, play a significant role in improving animal welfare, and improve the profitability of the pig farming industry. Intervacc will continue advancing the vaccine and prepare for GMP manufacturing and pivotal clinical studies.お知らせ • Feb 18Intervacc AB (publ), Annual General Meeting, May 13, 2026Intervacc AB (publ), Annual General Meeting, May 13, 2026.お知らせ • Feb 06Intervacc AB Announces Chief Executive Officer ChangesThe Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed Carl-Johan Dalsgaard as the new Chief Executive Officer and Group CEO with immediate effect. Carl-Johan Dalsgaard has an extensive clinical and scientific background, is a specialist physician, and holds a PhD from the Karolinska Institute. He has more than 25 years of experience in drug development at Astra/AstraZeneca and several biotech companies. Since 2000, Carl-Johan has been active as a Venture Partner at HealthCap, a leading European life science venture capital investor. He has served as CEO of several biotechnology companies, including Vicore Pharma (publ), Biolipox and Affibody. Carl-Johan also has many years of board experience, including Renovo (UK, public) and Tengion (US, public).お知らせ • Dec 26+ 4 more updatesIntervacc AB (publ) to Report Q3, 2026 Results on Nov 12, 2026Intervacc AB (publ) announced that they will report Q3, 2026 results on Nov 12, 2026お知らせ • Sep 27Intervacc Appoints Anna-Carin Lagerlöf as Sales and Marketing DirectorThe animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company's continued sales growth, with a particular focus on Strangvac - Intervacc's vaccine against strangles, a common infectious disease in horses. Anna-Carin brings extensive experience from the animal health market and joins Intervacc from IDEXX Laboratories, where she served as Country Manager for the Nordics. She will assume her new role in November and will also become a member of the company's executive management team.お知らせ • Aug 19Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and SloveniaIntervacc AB (publ) announced that its European distribution partner, Dechra Pharmaceuticals PLC, is launching Strangvac in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are expected to be available for delivery in these markets shortly.お知らせ • Mar 29Veterinary Medicines Directorate Approves Intervacc's Variation ApplicationIntervacc AB (publ) announced that the variation application previously submitted to the U.K's Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. As previously announced, the EMA has approved the corresponding variation application, and together these two approvals mark an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The improved processes have already been implemented in the production carried out during the autumn, and new vials has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.お知らせ • Feb 14+ 1 more updateIntervacc AB (Publ) Announces Approval from European Medicines AgencyIntervacc AB (publ) announced that the variation application previously submitted to the European Medicines Agency (EMA) has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. The approval from EMA marks an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The new processes have been developed over a period of approximately 1.5 years and aim to provide greater flexibility and stability in manufacturing. The improved processes have already been implemented in the production carried out during the autumn, and the vaccine has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.お知らせ • Dec 25Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million.Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million. Security Name: Shares Security Type: Common Stock Securities Offered: 265,076,924 Price\Range: SEK 0.85 Transaction Features: Rights Offeringお知らせ • Dec 24+ 4 more updatesIntervacc AB (publ) to Report Q2, 2025 Results on Aug 29, 2025Intervacc AB (publ) announced that they will report Q2, 2025 results on Aug 29, 2025Reported Earnings • Nov 15Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)Third quarter 2024 results: kr0.29 loss per share (improved from kr0.63 loss in 3Q 2023). Net loss: kr22.2m (loss narrowed 53% from 3Q 2023). Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.Reported Earnings • Aug 30Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)Second quarter 2024 results: kr0.24 loss per share (improved from kr0.32 loss in 2Q 2023). Net loss: kr17.8m (flat on 2Q 2023). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.Reported Earnings • May 16First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)First quarter 2024 results: kr0.23 loss per share (improved from kr0.35 loss in 1Q 2023). Net loss: kr17.4m (flat on 1Q 2023). Revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe.お知らせ • May 16Intervacc AB (Publ) Announces Board AppointmentsIntervacc AB (publ) announced at the AGM held on May 15, 2024, approved to elect Mathias Uhlen and Emil Billbäck, as Board members for the period up to and including the next AGM.お知らせ • Mar 05Intervacc AB (publ) Announces Changes in the Nomination CommitteeIntervacc AB (publ) announced that the composition of the Nomination Committee in the company was announced in a Press Release on October 30, 2023. Due to the fact that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden in December 2023 announced that they had chosen to resign from their assignment in the Nomination Committee, new members have been appointed to the Nomination Committee in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022. After the changes, the Nomination Committee in Intervacc before 2024 Annual General Meeting has the following composition: Magnus Lundberg, appointed by ownership group consisting of Håkan Björklund and Magnus Lundberg Christian Rudbäck, appointed by ownership group consisting of Jan-Ingmar Flock, NR Bergman Holding AB, Kenneth Janzon, Christian Rudbäck och Johan Virgin. Björn Sjöstrand, own possession.お知らせ • Feb 28Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)Intervacc AB (publ) announced that acting CEO Jonas Sohlman has been appointed as the new CEO of Intervacc AB and assumes the position immediately. The recruitment process that the previous board initiated has continued and now resulted in the appointment of Jonas Sohlman as the new CEO. Jonas has been working as the acting CEO since last August and assumes the role of CEO starting Feb. 28, 2024. Jonas Sohlman has extensive experience from leadership positions in publicly listed companies. He most recently held the role of CFO at Enorama Pharma. Additionally, he has solid experience within the equestrian industry and currently serves as the chairman of both Flyinge AB and Ridskolan Strömsholm AB.Reported Earnings • Feb 18Full year 2023 earnings released: kr1.69 loss per share (vs kr1.28 loss in FY 2022)Full year 2023 results: kr1.69 loss per share (further deteriorated from kr1.28 loss in FY 2022). Net loss: kr102.9m (loss widened 60% from FY 2022). Revenue is forecast to grow 113% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has fallen by 61% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 22+ 5 more updatesIntervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024Intervacc AB (publ) announced that they will report Q1, 2024 results on May 23, 2024お知らせ • Dec 21Intervacc AB (publ) Announces Changes in the Nomination CommitteeIntervacc AB (publ) announced that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden have resigned from the Nomination Committee.Board Change • Nov 29No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Camilla McCarthy is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Nov 24Intervacc AB (publ) Announces Executive ChangesIntervacc AB (publ) at its Extraordinary General Meeting held on 23 November 2023, resolved, in accordance with the shareholder group’s proposal, that the Board of Directors shall consist of five board members without deputies. Further, the EGM resolved, with the dismissal of all of the current board members, Björn Sjöstrand, Bengt Guss, Niels Holck, Stefan Ståhl, Boel Sundvall, Ed Torr and Michela de Carli, to, in accordance with the shareholder group’s proposal, elect Håkan Björklund, Jan-Ingmar Flock, Lisen Bratt Fredricson, Lennart Johansson and Camilla Ramfelt McCarthy, as new board members for the period until the end of the next Annual General Meeting. Håkan Björklund was elected chairperson of the Board of Directors.Reported Earnings • Nov 17Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)Third quarter 2023 results: kr0.78 loss per share (further deteriorated from kr0.29 loss in 3Q 2022). Net loss: kr47.5m (loss widened 225% from 3Q 2022). Revenue is forecast to grow 122% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.お知らせ • Oct 31Intervacc AB (publ) Announces Composition of Nomination CommitteeIntervacc AB (publ) announced the Nomination Committee consists of Ulrika Enhörning, appointed by Swedbank Robur Fonder; Thomas Ehlin, appointed by Fjärde AP-fonden and Magnus Lundberg, appointed by Håkan Björklund och Magnus Lundberg.Reported Earnings • Sep 01Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)Second quarter 2023 results: kr0.34 loss per share (further deteriorated from kr0.31 loss in 2Q 2022). Net loss: kr18.0m (loss widened 14% from 2Q 2022). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 22+ 1 more updateIntervacc AB (publ) Announces Executive ChangesThe Board of Directors for Intervacc AB (publ) has together with Andreas Andersson, made the decision that now is the right time for Andreas Andersson to leave his role as President and CEO, which he has held since late 2018. The Board of Directors have appointed Jonas Sohlman as acting President and CEO with immediate effect. The recruitment of a permanent President and CEO will commence as soon as possible, and, Andreas Andersson will be at the company´s disposal during this transition period. The board recognize and thank him for his work in developing the company to its position August 21, 2023 and launching Strangvac into the European market. Jonas Sohlman has a solid experience from leading positions in listed companies. Jonas last held the role as CFO at Enorama Pharma. In addition, Jonas has experience in the equine industry and is the Chairman of the Board of both Flyinge AB as well as for Ridskolan Strömsholm AB. Jonas has also been a professional breeder of show jumping horses.お知らせ • Aug 18Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from VinnovaIntervacc AB (publ) announced that it has been awarded an "industrial research" grant from Vinnova as part of a project with Testa Center, Uppsala, Sweden, to optimise the manufacturing processes of one component for a prototype vaccine for pigs. Intervacc's innovative technology utilises fusion proteins in vaccines to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. Streptococcus suis causes meningitis, sepsis and arthritis in young piglets, leading to significant costs to the pig industry throughout the world. Early proof-of-concept studies found that the consumption of colostrum from sows that were vaccinated with Intervacc's prototype vaccine against Streptococcus suis provided significant levels of protection to piglets at 4 and 7 weeks of age against challenge with a virulent strain of Streptococcus suis. Testa Center provide access to a lab environment with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new industrial research project provides a grant to Intervacc of 800, SEK funded by Vinnova, which corresponds to about 70% of the cost of this development phase at Testa Center.New Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr65m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr47m net loss in 2 years). Revenue is less than US$5m (kr12m revenue, or US$1.1m). Market cap is less than US$100m (€47.2m market cap, or US$50.8m).お知らせ • Jun 09Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,245,421 Price\Range: SEK 4.1 Transaction Features: Rights Offeringお知らせ • Jun 08Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board MemberIntervacc AB (publ) has held its Annual General Meeting (”AGM”) on 7 June 2023. To elect Boel Sundvall, as Board members for the period up to and including the next AGM.お知らせ • May 19The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 MonthsThe European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months. The Veterinary Medicines Directorate (VMD) the authority responsible for veterinary medicines in the UK, has previously approved the extension of the shelves life for Strangvac.お知らせ • May 10Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 MonthsIntervacc AB (publ) announced that the Veterinary Medicines Directorate (VMD) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months.Reported Earnings • May 04First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.35 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr17.5m (loss widened 63% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 31% per year.Breakeven Date Change • Mar 30Forecast breakeven date pushed back to 2025The analyst covering Intervacc previously expected the company to break even in 2024. New forecast suggests losses will reduce by 40% per year to 2024. The company is expected to make a profit of kr24.0m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Reported Earnings • Feb 18Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)Full year 2022 results: kr1.28 loss per share (further deteriorated from kr0.59 loss in FY 2021). Net loss: kr64.2m (loss widened 118% from FY 2021). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2024The 3 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of kr59.6m in 2024. Average annual earnings growth of 94% is required to achieve expected profit on schedule.お知らせ • Dec 28+ 5 more updatesIntervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023Intervacc AB (publ) announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 06, 2023お知らせ • Dec 14Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in ItalyIntervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.Reported Earnings • Nov 16Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Reported Earnings • Nov 12Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • Oct 13Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands ReleasedIntervacc AB (publ) announced that the first batch of Strangvac for sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands has been released.Reported Earnings • Sep 01Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)Second quarter 2022 results: kr0.31 loss per share (down from kr0.12 loss in 2Q 2021). Net loss: kr15.8m (loss widened 156% from 2Q 2021). Over the next year, revenue is forecast to grow 788%, compared to a 4.9% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 18Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the UkIntervacc AB (publ) announced that Strangvac is now available for sale in the UK. This week Strangvac has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease Strangles. Dechra will be distributing the vaccine in the UK and in a number of European countries.お知らせ • Jun 15Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022Intervacc AB (publ) elected Michela de Carli as Board Member at the Annual General Meeting held on June 14, 2022.お知らせ • Jun 01Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in DenmarkIntervacc announced that Strangvac, a vaccine against the highly contagious infectious disease equine strangles, has been released for sale in Denmark.Reported Earnings • May 21First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.13 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.13 loss in 1Q 2021). Net loss: kr10.7m (loss widened 66% from 1Q 2021). Over the next year, revenue is forecast to grow 601%, compared to a 30% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 19Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against MastitisIntervacc AB (publ) announced the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight: boldStaphylococcus aureus following successful safety and immunogenicity studies testing this prototype vaccine in pregnant heifers. This next phase of the project will be receiving a grant of 80k Euro from the EU's VetBioNet initiative. Mastitis is one of the most important diseases of dairy cattle worldwide. Over 2.6 million cases of disease, causing losses of approximately 600ME, occur in European farms each year. Approximately 25% of contagious mastitis cases are caused by Staphylococcus aureus and the control of mastitis is the most common reason for antibiotic use in dairy cows. Therefore, the development of safe and effective vaccines against Staphylococcus aureus would improve the health of dairy cows, reduce the use of antibiotics and reduce the impact of this disease on milk production. Vaccines against Staphylococcus aureus may also have wider potential to prevent disease in other animal species. Intervacc's programme to develop a vaccine against Staphylococcus aureus utilises the Matrix-V adjuvant in collaboration with Novavax. Safety and immunogenicity studies were conducted at the Swedish Livestock Research Centre, SLU Lövsta, Uppsala, Sweden and were co-financed by Vinnova. The next phase of the project will be receiving support from the EU's VetBioNet initiative, which is providing a grant of 80k Euros, representing around 30% of the estimated funding required.お知らせ • Apr 26Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in PigsIntervacc AB (publ) announced positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight:boldStreptococcus suis. The study showed that piglets from sows that had been vaccinated with a prototype fusion protein vaccine had significantly fewer clinical signs of disease compared to piglets from sows that received a placebo, adjuvant-only, vaccine following challenge with a virulent strain of Streptococcus suis at 4 or 7 weeks of age. Currently there are no commercial vaccines available that protect piglets from disease caused by Streptococcus suis. By fusing several important proteins of Streptococcus suis together, it is anticipated that the prototype vaccine will provide protection against a wide range of strain types, helping farmers to reduce the impact of this disease on the health of their animals and the cost to their business. The prototype vaccine was administered to pregnant sows by intramuscular injection making it simple and cost-effective. The proof-of-concept study was conducted at Moredun Scientific and has received funding from a European Commission grant through the Eurostars 2 programme, which is part of Horizon 2020.Reported Earnings • Apr 08Full year 2021 earnings released: kr0.59 loss per share (vs kr0.55 loss in FY 2020)Full year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Post-clinical trial products Approved (during full year): 1 Over the next year, revenue is forecast to grow 382%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Breakeven Date Change • Feb 22Forecast breakeven date pushed back to 2023The analyst covering Intervacc previously expected the company to break even in 2022. New forecast suggests losses will reduce by 22% to 2022. The company is expected to make a profit of kr4.00m in 2023. Average annual earnings growth of 104% is required to achieve expected profit on schedule.Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Revenue missed analyst estimates by 85%. Over the next year, revenue is forecast to grow 914%, compared to a 62% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 19Intervacc AB (publ), Annual General Meeting, Jun 14, 2022Intervacc AB (publ), Annual General Meeting, Jun 14, 2022.お知らせ • Feb 16Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.SIntervacc AB (publ) announced that the Company's application for a Permit for Sale and Distribution of Strangvac in the U.S. has been submitted to the U.S. Department of Agriculture (USDA). Intervacc is seeking approval for Strangvac, a vaccine against the highly contagious equine disease strangles that affects horses worldwide. Strangvac has been approved for use in the European Union, the United Kingdom, Norway, and Iceland since the autumn of 2021. The Strangvac vaccine has been developed with innovative technology and is based on recombinant fusion proteins. The research that forms the basis for the vaccine's technical platform has been carried out together with researchers at the Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU.お知らせ • Feb 01Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European MarketsThe European patent for Strangvac, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the Netherlands, Italy, Ireland, France, Spain, Germany and Austria will be extended until May 2036. Supplementary protection certificates (SPCs) are an intellectual property right that serves as an extension of the monopoly conferred by a patent, however limited to the specific pharmaceutical and plant protection product authorised by regulatory authorities and protected by the patent. The EU wishes to provide sufficient protection for these products in the interest of public health and to encourage innovation in these areas to generate smart growth and jobs. Supplementary protection certificates aim to offset the loss of patent protection for pharmaceutical and plant protection products that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.Reported Earnings • Nov 12Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr8.32m (loss widened 30% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.70m in 2022. Average annual earnings growth of 129% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 04Forecast to breakeven in 2023The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr69.3m in 2023. Average annual earnings growth of 128% is required to achieve expected profit on schedule.Reported Earnings • Sep 01Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)Second quarter 2021 results: Net loss: kr6.15m (loss widened 6.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 03Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UKIntervacc AB announced that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation for Strangvac within the UK. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. An approval after the positive outcome is expected after 40 days.お知らせ • Jun 18Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EUIntervacc AB announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac® within the EU. Strangvac® is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2021. The vaccine has been developed with an innovative technology based on recombinant fusion proteins. The extensive research collaboration behind the vaccine's technical platform has been achieved together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU. Strangvac®, is injected intramuscularly and is totally devoid of any living infectious agent. The process towards the approval of Strangvac® for use in the UK is on-track and the company anticipates receiving a positive opinion before the end of July.Executive Departure • Jun 16Independent Director Newton Aguiar has left the companyOn the 9th of June, Newton Aguiar's tenure as Independent Director ended. As of March 2021, Newton still personally held 2.85m shares (€21m worth at the time). Newton is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.38 years, which is considered inexperienced in the Simply Wall St Risk Model.Breakeven Date Change • May 27Forecast breakeven pushed back to 2023The 2 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2022. The company is expected to make a profit of kr69.3m in 2023. Average annual earnings growth of 118% is required to achieve expected profit on schedule.Reported Earnings • May 22First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)First quarter 2021 results: Net loss: kr6.48m (loss widened 2.6% from 1Q 2020).Recent Insider Transactions • Apr 18Independent Director recently sold €2.9m worth of stockOn the 13th of April, Newton Aguiar sold around 345k shares on-market at roughly €8.35 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Is New 90 Day High Low • Feb 27New 90-day high: €7.54The company is up 76% from its price of €4.29 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.97 per share.Reported Earnings • Feb 20Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 8.2% from FY 2019).お知らせ • Feb 19+ 3 more updatesIntervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021Intervacc AB (publ) announced that they will report Q2, 2021 results on Sep 03, 2021お知らせ • Feb 18Intervacc AB (publ), Annual General Meeting, Jun 09, 2021Intervacc AB (publ), Annual General Meeting, Jun 09, 2021.Is New 90 Day High Low • Feb 10New 90-day high: €5.55The company is up 20% from its price of €4.64 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.お知らせ • Nov 25Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for StrangvacIntervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease strangles. Emma Hartman has a DVM degree and most recently comes from MSD Animal Health, where she held the position of Nordic product manager for equine and ruminant products. Intervacc develops vaccines which aim to improve animal health. Earlier this year the company submitted its application for the granting of a Community marketing authorization for Strangvac to the European Medicines Agency (EMA). Equine strangles, caused by the bacterium Streptococcus equi, is the most common infectious disease of horses worldwide. The disease is characterized by the formation of abscesses in the head and neck of horses, which can literally strangle the horse to death. The strangles bacteria can also hide in apparently healthy recovered horses, called carriers, which enable it to persist and spread to new premises. Outbreaks of strangles can take a long time to resolve, requiring the implementation of many measures to limit the spread of infection and ultimately, eradicate the disease from an affected stable. Therefore, strangles is a priority animal health issue among the world's equine veterinarians.Reported Earnings • Nov 16Third quarter 2020 earnings released: kr0.13 loss per shareThird quarter 2020 results: Net loss: kr6.40m (loss widened 2.6% from 3Q 2019).Is New 90 Day High Low • Oct 05New 90-day high: €3.91The company is up 48% from its price of €2.64 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Sep 19New 90-day high: €3.57The company is up 64% from its price of €2.17 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.業績と収益の成長予測DB:2E9 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028164N/A-65-56112/31/202730-83-81-69112/31/202616-82-74-5913/31/202619-89-71-66N/A12/31/202520-81-67-66N/A9/30/202521-63-70-69N/A6/30/202518-71-54-53N/A3/31/202514-71-49-49N/A12/31/202412-76-54-53N/A9/30/20249-77-49-49N/A6/30/202410-103-50-49N/A3/31/20249-103-54-52N/A12/31/20238-103-48-46N/A9/30/202310-106-57-55N/A6/30/202310-73-60-57N/A3/31/202312-71-65-62N/A12/31/202212-64-76-70N/A9/30/202210-50-70-57N/A6/30/202210-44-65-47N/A3/31/20229-34-55-33N/A12/31/20219-29-49-25N/A9/30/20219-28-43-24N/A6/30/20218-26-38-22N/A3/31/20217-26-36-23N/A12/31/20207-26-31-20N/A9/30/20207-26-35-18N/A6/30/20208-26-39-15N/A3/31/20209-29-45-10N/A12/31/201914-28N/A-3N/A9/30/201916-27N/A0N/A6/30/201926-26N/A6N/A3/31/201941-29N/A0N/A12/31/201838-27N/A-4N/A9/30/201838-27N/A-12N/A6/30/201838-24N/A-17N/A3/31/201843-16N/A-28N/A12/31/201750-13N/A-19N/A9/30/201752-11N/A-17N/A6/30/201756-9N/A-23N/A3/31/201763-6N/A-1N/A12/31/201658-7N/A-4N/A12/31/2015650N/A-19N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2E9今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 2E9今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 2E9今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 2E9の収益 ( 87.2% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 2E9の収益 ( 87.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2E9 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:12終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Intervacc AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Jakob LembkeABG Sundal Collier SponsoredLars HevrengDanske BankKlas PalinDNB Carnegie Commissioned Research
Breakeven Date Change • Mar 30Forecast breakeven date pushed back to 2025The analyst covering Intervacc previously expected the company to break even in 2024. New forecast suggests losses will reduce by 40% per year to 2024. The company is expected to make a profit of kr24.0m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2024The 3 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of kr59.6m in 2024. Average annual earnings growth of 94% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 22Forecast breakeven date pushed back to 2023The analyst covering Intervacc previously expected the company to break even in 2022. New forecast suggests losses will reduce by 22% to 2022. The company is expected to make a profit of kr4.00m in 2023. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.70m in 2022. Average annual earnings growth of 129% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 04Forecast to breakeven in 2023The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr69.3m in 2023. Average annual earnings growth of 128% is required to achieve expected profit on schedule.
Breakeven Date Change • May 27Forecast breakeven pushed back to 2023The 2 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2022. The company is expected to make a profit of kr69.3m in 2023. Average annual earnings growth of 118% is required to achieve expected profit on schedule.
Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Camilla McCarthy is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 15Intervacc AB (Publ) Appoints Emil Billbäck as ChairpersonIntervacc AB (publ) held its Annual General Meeting on 13 May 2026, and Emil Billbäck was elected as the Board of Directors' new chairperson for the period up to and including the next AGM.
お知らせ • May 13Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026Intervacc AB (publ) announced the recruitment of Lars Stubberud as Chief Technology Officer (CTO), effective July 15, 2026. Lars Stubberud, M.Sc. Pharm, Ph.D., has more than 30 years' experience from the pharmaceutical industry, with responsibilities and expertise spanning broad CMC, product development, formulation, technology transfer, supply chain management, quality control and CMC regulatory affairs. He most recently held the position of Vice President Quality Assurance, Quality Control/Analytical Development at Calliditas Therapeutics AB, Stockholm, Sweden. The management team also comprises Jan Persson, CFO, Anna-Carin Lagerlöf, Head of Sales and Marketing, and Andrew Waller, Chief Scientific Officer.
お知らせ • Apr 18Intervacc AB Announces Approval and Launch of Strangvac Vaccine in IcelandIntervacc AB (publ) announced that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses worldwide. However, it has not been permitted to import horses into Iceland for over 1,000 years and so this country retains the only strangles-free horse population in the world. Whilst horses within Iceland do not develop strangles, they have no natural immunity and are highly susceptible to this disease should they come into contact with S. equi. This has been a longstanding issue for horses exported from Iceland to other parts of the world. Strangvac is the only vaccine against strangles that generates a protective immune response, whilst still permitting the diagnosis of horses that have been exposed to, or are infected with, S. equi. This unique feature enables continued disease surveillance to provide evidence in support of Iceland's disease-free status and the protection of exported horses, which is important for Iceland's veterinarians and horse breeders, as well as the new owners. This approval is particularly noteworthy as the vaccination of horses to protect against infectious diseases is generally prohibited in Iceland, making the decision both unique and highly significant.
お知らせ • Mar 20Intervacc AB Publ Announces Breakthrough Protection Against Streptococcus Suis Infection in PigletsIntervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating sows and transferring maternal immunity to piglets. The protection was proven in two separate challenge studies. Streptococcus suis is an important worldwide endemic swine pathogen, which causes meningitis, septicemia, arthritis, and endocarditis in weaned piglets between 4 and 10 weeks of age. Mortality rates can be as high as 20% in some farms and the total cost of S. suis infection in pigs is estimated to more than EUR 250 million annually in Europe alone. As of today, there are no approved vaccines available against S. suis infection in pigs. The experimental infection model involved the intravenous administration of a high dose of the virulent serotype 9 strain of S. suis (ST16) to induce systemic disease. The study showed that vaccination of pregnant sows was safe and provided statistically significant protection (total clinical score; p = 0.017) to piglets compared with piglets from an unvaccinated control group. The vaccine has previously conferred statistically significant protection to piglets against a virulent serotype 2 strain (ST1). The vaccine is administered to pregnant sows by intramuscular injection making it simple and cost-effective for pig farmers to use. The subunit vaccine, which is based on Intervacc's platform using recombinant fusion proteins, is designed to give protection against a wide range of S. suis strain types, using conserved, immunogenic, and virulence-associated proteins from S. suis. S. suis serotype 2 strains are the most common global cause of severe disease in piglets. Serotype 9 is currently less prevalent than serotype 2 but is increasingly responsible for severe pig diseases in Europe. Protection from a vaccine against multiple S. suis serotypes has been sought after by the pig farming industry for many years. Intervacc is the first company to show that a vaccine protected piglets against the highly virulent serotypes 2 (ST1) and 9 (ST16). This is a major breakthrough since the strains used in the studies are not closely related and the vaccine was only administered to pregnant sows with subsequent transfer of maternal immunity to their piglets. It is estimated that S. suis accounts for one-third of the total antibiotic usage in weaner pigs. A safe and efficacious vaccine against S. suis would reduce the need for antibiotics and the global threat from antimicrobial resistance, play a significant role in improving animal welfare, and improve the profitability of the pig farming industry. Intervacc will continue advancing the vaccine and prepare for GMP manufacturing and pivotal clinical studies.
お知らせ • Feb 18Intervacc AB (publ), Annual General Meeting, May 13, 2026Intervacc AB (publ), Annual General Meeting, May 13, 2026.
お知らせ • Feb 06Intervacc AB Announces Chief Executive Officer ChangesThe Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed Carl-Johan Dalsgaard as the new Chief Executive Officer and Group CEO with immediate effect. Carl-Johan Dalsgaard has an extensive clinical and scientific background, is a specialist physician, and holds a PhD from the Karolinska Institute. He has more than 25 years of experience in drug development at Astra/AstraZeneca and several biotech companies. Since 2000, Carl-Johan has been active as a Venture Partner at HealthCap, a leading European life science venture capital investor. He has served as CEO of several biotechnology companies, including Vicore Pharma (publ), Biolipox and Affibody. Carl-Johan also has many years of board experience, including Renovo (UK, public) and Tengion (US, public).
お知らせ • Dec 26+ 4 more updatesIntervacc AB (publ) to Report Q3, 2026 Results on Nov 12, 2026Intervacc AB (publ) announced that they will report Q3, 2026 results on Nov 12, 2026
お知らせ • Sep 27Intervacc Appoints Anna-Carin Lagerlöf as Sales and Marketing DirectorThe animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company's continued sales growth, with a particular focus on Strangvac - Intervacc's vaccine against strangles, a common infectious disease in horses. Anna-Carin brings extensive experience from the animal health market and joins Intervacc from IDEXX Laboratories, where she served as Country Manager for the Nordics. She will assume her new role in November and will also become a member of the company's executive management team.
お知らせ • Aug 19Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and SloveniaIntervacc AB (publ) announced that its European distribution partner, Dechra Pharmaceuticals PLC, is launching Strangvac in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are expected to be available for delivery in these markets shortly.
お知らせ • Mar 29Veterinary Medicines Directorate Approves Intervacc's Variation ApplicationIntervacc AB (publ) announced that the variation application previously submitted to the U.K's Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. As previously announced, the EMA has approved the corresponding variation application, and together these two approvals mark an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The improved processes have already been implemented in the production carried out during the autumn, and new vials has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.
お知らせ • Feb 14+ 1 more updateIntervacc AB (Publ) Announces Approval from European Medicines AgencyIntervacc AB (publ) announced that the variation application previously submitted to the European Medicines Agency (EMA) has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. The approval from EMA marks an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The new processes have been developed over a period of approximately 1.5 years and aim to provide greater flexibility and stability in manufacturing. The improved processes have already been implemented in the production carried out during the autumn, and the vaccine has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.
お知らせ • Dec 25Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million.Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million. Security Name: Shares Security Type: Common Stock Securities Offered: 265,076,924 Price\Range: SEK 0.85 Transaction Features: Rights Offering
お知らせ • Dec 24+ 4 more updatesIntervacc AB (publ) to Report Q2, 2025 Results on Aug 29, 2025Intervacc AB (publ) announced that they will report Q2, 2025 results on Aug 29, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)Third quarter 2024 results: kr0.29 loss per share (improved from kr0.63 loss in 3Q 2023). Net loss: kr22.2m (loss narrowed 53% from 3Q 2023). Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.
Reported Earnings • Aug 30Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)Second quarter 2024 results: kr0.24 loss per share (improved from kr0.32 loss in 2Q 2023). Net loss: kr17.8m (flat on 2Q 2023). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
Reported Earnings • May 16First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)First quarter 2024 results: kr0.23 loss per share (improved from kr0.35 loss in 1Q 2023). Net loss: kr17.4m (flat on 1Q 2023). Revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
お知らせ • May 16Intervacc AB (Publ) Announces Board AppointmentsIntervacc AB (publ) announced at the AGM held on May 15, 2024, approved to elect Mathias Uhlen and Emil Billbäck, as Board members for the period up to and including the next AGM.
お知らせ • Mar 05Intervacc AB (publ) Announces Changes in the Nomination CommitteeIntervacc AB (publ) announced that the composition of the Nomination Committee in the company was announced in a Press Release on October 30, 2023. Due to the fact that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden in December 2023 announced that they had chosen to resign from their assignment in the Nomination Committee, new members have been appointed to the Nomination Committee in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022. After the changes, the Nomination Committee in Intervacc before 2024 Annual General Meeting has the following composition: Magnus Lundberg, appointed by ownership group consisting of Håkan Björklund and Magnus Lundberg Christian Rudbäck, appointed by ownership group consisting of Jan-Ingmar Flock, NR Bergman Holding AB, Kenneth Janzon, Christian Rudbäck och Johan Virgin. Björn Sjöstrand, own possession.
お知らせ • Feb 28Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)Intervacc AB (publ) announced that acting CEO Jonas Sohlman has been appointed as the new CEO of Intervacc AB and assumes the position immediately. The recruitment process that the previous board initiated has continued and now resulted in the appointment of Jonas Sohlman as the new CEO. Jonas has been working as the acting CEO since last August and assumes the role of CEO starting Feb. 28, 2024. Jonas Sohlman has extensive experience from leadership positions in publicly listed companies. He most recently held the role of CFO at Enorama Pharma. Additionally, he has solid experience within the equestrian industry and currently serves as the chairman of both Flyinge AB and Ridskolan Strömsholm AB.
Reported Earnings • Feb 18Full year 2023 earnings released: kr1.69 loss per share (vs kr1.28 loss in FY 2022)Full year 2023 results: kr1.69 loss per share (further deteriorated from kr1.28 loss in FY 2022). Net loss: kr102.9m (loss widened 60% from FY 2022). Revenue is forecast to grow 113% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has fallen by 61% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 22+ 5 more updatesIntervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024Intervacc AB (publ) announced that they will report Q1, 2024 results on May 23, 2024
お知らせ • Dec 21Intervacc AB (publ) Announces Changes in the Nomination CommitteeIntervacc AB (publ) announced that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden have resigned from the Nomination Committee.
Board Change • Nov 29No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Camilla McCarthy is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 24Intervacc AB (publ) Announces Executive ChangesIntervacc AB (publ) at its Extraordinary General Meeting held on 23 November 2023, resolved, in accordance with the shareholder group’s proposal, that the Board of Directors shall consist of five board members without deputies. Further, the EGM resolved, with the dismissal of all of the current board members, Björn Sjöstrand, Bengt Guss, Niels Holck, Stefan Ståhl, Boel Sundvall, Ed Torr and Michela de Carli, to, in accordance with the shareholder group’s proposal, elect Håkan Björklund, Jan-Ingmar Flock, Lisen Bratt Fredricson, Lennart Johansson and Camilla Ramfelt McCarthy, as new board members for the period until the end of the next Annual General Meeting. Håkan Björklund was elected chairperson of the Board of Directors.
Reported Earnings • Nov 17Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)Third quarter 2023 results: kr0.78 loss per share (further deteriorated from kr0.29 loss in 3Q 2022). Net loss: kr47.5m (loss widened 225% from 3Q 2022). Revenue is forecast to grow 122% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
お知らせ • Oct 31Intervacc AB (publ) Announces Composition of Nomination CommitteeIntervacc AB (publ) announced the Nomination Committee consists of Ulrika Enhörning, appointed by Swedbank Robur Fonder; Thomas Ehlin, appointed by Fjärde AP-fonden and Magnus Lundberg, appointed by Håkan Björklund och Magnus Lundberg.
Reported Earnings • Sep 01Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)Second quarter 2023 results: kr0.34 loss per share (further deteriorated from kr0.31 loss in 2Q 2022). Net loss: kr18.0m (loss widened 14% from 2Q 2022). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 22+ 1 more updateIntervacc AB (publ) Announces Executive ChangesThe Board of Directors for Intervacc AB (publ) has together with Andreas Andersson, made the decision that now is the right time for Andreas Andersson to leave his role as President and CEO, which he has held since late 2018. The Board of Directors have appointed Jonas Sohlman as acting President and CEO with immediate effect. The recruitment of a permanent President and CEO will commence as soon as possible, and, Andreas Andersson will be at the company´s disposal during this transition period. The board recognize and thank him for his work in developing the company to its position August 21, 2023 and launching Strangvac into the European market. Jonas Sohlman has a solid experience from leading positions in listed companies. Jonas last held the role as CFO at Enorama Pharma. In addition, Jonas has experience in the equine industry and is the Chairman of the Board of both Flyinge AB as well as for Ridskolan Strömsholm AB. Jonas has also been a professional breeder of show jumping horses.
お知らせ • Aug 18Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from VinnovaIntervacc AB (publ) announced that it has been awarded an "industrial research" grant from Vinnova as part of a project with Testa Center, Uppsala, Sweden, to optimise the manufacturing processes of one component for a prototype vaccine for pigs. Intervacc's innovative technology utilises fusion proteins in vaccines to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. Streptococcus suis causes meningitis, sepsis and arthritis in young piglets, leading to significant costs to the pig industry throughout the world. Early proof-of-concept studies found that the consumption of colostrum from sows that were vaccinated with Intervacc's prototype vaccine against Streptococcus suis provided significant levels of protection to piglets at 4 and 7 weeks of age against challenge with a virulent strain of Streptococcus suis. Testa Center provide access to a lab environment with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new industrial research project provides a grant to Intervacc of 800, SEK funded by Vinnova, which corresponds to about 70% of the cost of this development phase at Testa Center.
New Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr65m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr47m net loss in 2 years). Revenue is less than US$5m (kr12m revenue, or US$1.1m). Market cap is less than US$100m (€47.2m market cap, or US$50.8m).
お知らせ • Jun 09Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,245,421 Price\Range: SEK 4.1 Transaction Features: Rights Offering
お知らせ • Jun 08Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board MemberIntervacc AB (publ) has held its Annual General Meeting (”AGM”) on 7 June 2023. To elect Boel Sundvall, as Board members for the period up to and including the next AGM.
お知らせ • May 19The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 MonthsThe European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months. The Veterinary Medicines Directorate (VMD) the authority responsible for veterinary medicines in the UK, has previously approved the extension of the shelves life for Strangvac.
お知らせ • May 10Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 MonthsIntervacc AB (publ) announced that the Veterinary Medicines Directorate (VMD) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months.
Reported Earnings • May 04First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.35 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr17.5m (loss widened 63% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 31% per year.
Breakeven Date Change • Mar 30Forecast breakeven date pushed back to 2025The analyst covering Intervacc previously expected the company to break even in 2024. New forecast suggests losses will reduce by 40% per year to 2024. The company is expected to make a profit of kr24.0m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)Full year 2022 results: kr1.28 loss per share (further deteriorated from kr0.59 loss in FY 2021). Net loss: kr64.2m (loss widened 118% from FY 2021). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2024The 3 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of kr59.6m in 2024. Average annual earnings growth of 94% is required to achieve expected profit on schedule.
お知らせ • Dec 28+ 5 more updatesIntervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023Intervacc AB (publ) announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 06, 2023
お知らせ • Dec 14Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in ItalyIntervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.
Reported Earnings • Nov 16Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 12Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • Oct 13Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands ReleasedIntervacc AB (publ) announced that the first batch of Strangvac for sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands has been released.
Reported Earnings • Sep 01Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)Second quarter 2022 results: kr0.31 loss per share (down from kr0.12 loss in 2Q 2021). Net loss: kr15.8m (loss widened 156% from 2Q 2021). Over the next year, revenue is forecast to grow 788%, compared to a 4.9% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 18Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the UkIntervacc AB (publ) announced that Strangvac is now available for sale in the UK. This week Strangvac has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease Strangles. Dechra will be distributing the vaccine in the UK and in a number of European countries.
お知らせ • Jun 15Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022Intervacc AB (publ) elected Michela de Carli as Board Member at the Annual General Meeting held on June 14, 2022.
お知らせ • Jun 01Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in DenmarkIntervacc announced that Strangvac, a vaccine against the highly contagious infectious disease equine strangles, has been released for sale in Denmark.
Reported Earnings • May 21First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.13 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.13 loss in 1Q 2021). Net loss: kr10.7m (loss widened 66% from 1Q 2021). Over the next year, revenue is forecast to grow 601%, compared to a 30% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 19Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against MastitisIntervacc AB (publ) announced the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight: boldStaphylococcus aureus following successful safety and immunogenicity studies testing this prototype vaccine in pregnant heifers. This next phase of the project will be receiving a grant of 80k Euro from the EU's VetBioNet initiative. Mastitis is one of the most important diseases of dairy cattle worldwide. Over 2.6 million cases of disease, causing losses of approximately 600ME, occur in European farms each year. Approximately 25% of contagious mastitis cases are caused by Staphylococcus aureus and the control of mastitis is the most common reason for antibiotic use in dairy cows. Therefore, the development of safe and effective vaccines against Staphylococcus aureus would improve the health of dairy cows, reduce the use of antibiotics and reduce the impact of this disease on milk production. Vaccines against Staphylococcus aureus may also have wider potential to prevent disease in other animal species. Intervacc's programme to develop a vaccine against Staphylococcus aureus utilises the Matrix-V adjuvant in collaboration with Novavax. Safety and immunogenicity studies were conducted at the Swedish Livestock Research Centre, SLU Lövsta, Uppsala, Sweden and were co-financed by Vinnova. The next phase of the project will be receiving support from the EU's VetBioNet initiative, which is providing a grant of 80k Euros, representing around 30% of the estimated funding required.
お知らせ • Apr 26Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in PigsIntervacc AB (publ) announced positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight:boldStreptococcus suis. The study showed that piglets from sows that had been vaccinated with a prototype fusion protein vaccine had significantly fewer clinical signs of disease compared to piglets from sows that received a placebo, adjuvant-only, vaccine following challenge with a virulent strain of Streptococcus suis at 4 or 7 weeks of age. Currently there are no commercial vaccines available that protect piglets from disease caused by Streptococcus suis. By fusing several important proteins of Streptococcus suis together, it is anticipated that the prototype vaccine will provide protection against a wide range of strain types, helping farmers to reduce the impact of this disease on the health of their animals and the cost to their business. The prototype vaccine was administered to pregnant sows by intramuscular injection making it simple and cost-effective. The proof-of-concept study was conducted at Moredun Scientific and has received funding from a European Commission grant through the Eurostars 2 programme, which is part of Horizon 2020.
Reported Earnings • Apr 08Full year 2021 earnings released: kr0.59 loss per share (vs kr0.55 loss in FY 2020)Full year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Post-clinical trial products Approved (during full year): 1 Over the next year, revenue is forecast to grow 382%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Breakeven Date Change • Feb 22Forecast breakeven date pushed back to 2023The analyst covering Intervacc previously expected the company to break even in 2022. New forecast suggests losses will reduce by 22% to 2022. The company is expected to make a profit of kr4.00m in 2023. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Revenue missed analyst estimates by 85%. Over the next year, revenue is forecast to grow 914%, compared to a 62% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 19Intervacc AB (publ), Annual General Meeting, Jun 14, 2022Intervacc AB (publ), Annual General Meeting, Jun 14, 2022.
お知らせ • Feb 16Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.SIntervacc AB (publ) announced that the Company's application for a Permit for Sale and Distribution of Strangvac in the U.S. has been submitted to the U.S. Department of Agriculture (USDA). Intervacc is seeking approval for Strangvac, a vaccine against the highly contagious equine disease strangles that affects horses worldwide. Strangvac has been approved for use in the European Union, the United Kingdom, Norway, and Iceland since the autumn of 2021. The Strangvac vaccine has been developed with innovative technology and is based on recombinant fusion proteins. The research that forms the basis for the vaccine's technical platform has been carried out together with researchers at the Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU.
お知らせ • Feb 01Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European MarketsThe European patent for Strangvac, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the Netherlands, Italy, Ireland, France, Spain, Germany and Austria will be extended until May 2036. Supplementary protection certificates (SPCs) are an intellectual property right that serves as an extension of the monopoly conferred by a patent, however limited to the specific pharmaceutical and plant protection product authorised by regulatory authorities and protected by the patent. The EU wishes to provide sufficient protection for these products in the interest of public health and to encourage innovation in these areas to generate smart growth and jobs. Supplementary protection certificates aim to offset the loss of patent protection for pharmaceutical and plant protection products that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr8.32m (loss widened 30% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.70m in 2022. Average annual earnings growth of 129% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 04Forecast to breakeven in 2023The 2 analysts covering Intervacc expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr69.3m in 2023. Average annual earnings growth of 128% is required to achieve expected profit on schedule.
Reported Earnings • Sep 01Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)Second quarter 2021 results: Net loss: kr6.15m (loss widened 6.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 03Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UKIntervacc AB announced that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation for Strangvac within the UK. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. An approval after the positive outcome is expected after 40 days.
お知らせ • Jun 18Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EUIntervacc AB announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac® within the EU. Strangvac® is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2021. The vaccine has been developed with an innovative technology based on recombinant fusion proteins. The extensive research collaboration behind the vaccine's technical platform has been achieved together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU. Strangvac®, is injected intramuscularly and is totally devoid of any living infectious agent. The process towards the approval of Strangvac® for use in the UK is on-track and the company anticipates receiving a positive opinion before the end of July.
Executive Departure • Jun 16Independent Director Newton Aguiar has left the companyOn the 9th of June, Newton Aguiar's tenure as Independent Director ended. As of March 2021, Newton still personally held 2.85m shares (€21m worth at the time). Newton is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.38 years, which is considered inexperienced in the Simply Wall St Risk Model.
Breakeven Date Change • May 27Forecast breakeven pushed back to 2023The 2 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2022. The company is expected to make a profit of kr69.3m in 2023. Average annual earnings growth of 118% is required to achieve expected profit on schedule.
Reported Earnings • May 22First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)First quarter 2021 results: Net loss: kr6.48m (loss widened 2.6% from 1Q 2020).
Recent Insider Transactions • Apr 18Independent Director recently sold €2.9m worth of stockOn the 13th of April, Newton Aguiar sold around 345k shares on-market at roughly €8.35 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Is New 90 Day High Low • Feb 27New 90-day high: €7.54The company is up 76% from its price of €4.29 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.97 per share.
Reported Earnings • Feb 20Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 8.2% from FY 2019).
お知らせ • Feb 19+ 3 more updatesIntervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021Intervacc AB (publ) announced that they will report Q2, 2021 results on Sep 03, 2021
お知らせ • Feb 18Intervacc AB (publ), Annual General Meeting, Jun 09, 2021Intervacc AB (publ), Annual General Meeting, Jun 09, 2021.
Is New 90 Day High Low • Feb 10New 90-day high: €5.55The company is up 20% from its price of €4.64 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
お知らせ • Nov 25Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for StrangvacIntervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease strangles. Emma Hartman has a DVM degree and most recently comes from MSD Animal Health, where she held the position of Nordic product manager for equine and ruminant products. Intervacc develops vaccines which aim to improve animal health. Earlier this year the company submitted its application for the granting of a Community marketing authorization for Strangvac to the European Medicines Agency (EMA). Equine strangles, caused by the bacterium Streptococcus equi, is the most common infectious disease of horses worldwide. The disease is characterized by the formation of abscesses in the head and neck of horses, which can literally strangle the horse to death. The strangles bacteria can also hide in apparently healthy recovered horses, called carriers, which enable it to persist and spread to new premises. Outbreaks of strangles can take a long time to resolve, requiring the implementation of many measures to limit the spread of infection and ultimately, eradicate the disease from an affected stable. Therefore, strangles is a priority animal health issue among the world's equine veterinarians.
Reported Earnings • Nov 16Third quarter 2020 earnings released: kr0.13 loss per shareThird quarter 2020 results: Net loss: kr6.40m (loss widened 2.6% from 3Q 2019).
Is New 90 Day High Low • Oct 05New 90-day high: €3.91The company is up 48% from its price of €2.64 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Sep 19New 90-day high: €3.57The company is up 64% from its price of €2.17 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.